Aytu BioPharma (NASDAQ:AYTU) Cut to “Buy” at Wall Street Zen

Aytu BioPharma (NASDAQ:AYTU) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other equities analysts have also recently commented on the stock. Ascendiant Capital Markets initiated coverage on shares of Aytu BioPharma in a research note on Monday, June 30th. They set a “buy” rating and a $12.00 price target for the company. Lake Street Capital began coverage on Aytu BioPharma in a research report on Tuesday. They set a “buy” rating and a $8.00 target price for the company.

Aytu BioPharma Trading Up 5.9%

Shares of NASDAQ AYTU opened at $2.43 on Friday. Aytu BioPharma has a 1-year low of $0.95 and a 1-year high of $2.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.03 and a quick ratio of 0.87. The business’s 50 day moving average is $1.82 and its two-hundred day moving average is $1.53. The stock has a market capitalization of $21.78 million, a P/E ratio of -3.37 and a beta of 0.13.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Wednesday, May 14th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.37. The company had revenue of $18.45 million for the quarter, compared to analyst estimates of $13.74 million. Aytu BioPharma had a return on equity of 3.51% and a net margin of 2.37%.

Institutional Trading of Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC raised its stake in Aytu BioPharma Inc. (NASDAQ:AYTU) by 13.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 463,721 shares of the company’s stock after buying an additional 56,172 shares during the period. Stonepine Capital Management LLC owned about 7.52% of Aytu BioPharma worth $556,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.